Drug profile · INN
methotrexate sodium
METHOTREXATE SODIUM
methotrexate sodium (METHOTREXATE SODIUM) is a dihydrofolate reductase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — methotrexate sodium
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
methotrexate sodium (METHOTREXATE SODIUM) is a dihydrofolate reductase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Dihydrofolate reductase inhibitor
Primary target: Dihydrofolate reductase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is methotrexate sodium?
methotrexate sodium (METHOTREXATE SODIUM) is a dihydrofolate reductase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for methotrexate sodium?
METHOTREXATE SODIUM is a marketed brand name for methotrexate sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of methotrexate sodium?
methotrexate sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.